Grand Rounds

Optimizing Treatment Strategies in Patients With Polycythemia Vera Who Develop a Thrombotic Event on Frontline Therapy

Lindsey Lyle,(1) MS, PA-C, and Julie Huynh-Lu,(2) PA

From (1)University of Colorado Cancer Center, Aurora, Colorado; (2)The University of Texas MD Anderson Cancer Center, Houston, Texas

Authors’ disclosures of conflicts of interest are found at the end of this article.

Correspondence to: Lindsey Lyle, MS, PA-C, University of Colorado, 1665 Aurora Court, Aurora, CO 80045. E-mail: lindsey.lyle@cuanschutz.edu


J Adv Pract Oncol 2020;11(Suppl 2):20–26 | https://doi.org/10.6004/jadpro.2020.11.7.13 | © 2020 Harborside™


  

ABSTRACT

Advanced practitioners are ideal advocates for their patients with polycythemia vera who have had a thrombotic event to ensure that secondary prevention measures are in place, including the implementation of close monitoring and tailoring therapy to meet individual needs. Being equipped with the medical knowledge to identify patients who are displaying signs and symptoms of resistance or intolerance is key to minimizing disease- or therapy-related complications and ultimately provide personalized therapy for each patient. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2020 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.